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Dietary and metabolic therapies have been attempted in a wide variety of neurological dis-
eases, including epilepsy, headache, neurotrauma, Alzheimer disease, Parkinson disease,
sleep disorders, brain cancer, autism, pain, and multiple sclerosis. The impetus for using
various diets to treat – or at least ameliorate symptoms of – these disorders stems from
both a lack of effectiveness of pharmacological therapies, and also the intrinsic appeal
of implementing a more “natural” treatment. The enormous spectrum of pathophysio-
logical mechanisms underlying the aforementioned diseases would suggest a degree of
complexity that cannot be impacted universally by any single dietary treatment.Yet, it is con-
ceivable that alterations in certain dietary constituents could affect the course and impact
the outcome of these brain disorders. Further, it is possible that a ﬁnal common neurometa-
bolic pathway might be inﬂuenced by a variety of dietary interventions. The most notable
example of a dietary treatment with proven efﬁcacy against a neurological condition is the
high-fat, low-carbohydrate ketogenic diet (KD) used in patients with medically intractable
epilepsy.While the mechanisms through which the KD works remain unclear, there is now
compelling evidence that its efﬁcacy is likely related to the normalization of aberrant energy
metabolism.The concept that many neurological conditions are linked pathophysiologically
to energy dysregulation could well provide a common research and experimental therapeu-
tics platform, from which the course of several neurological diseases could be favorably
inﬂuenced by dietary means. Here we provide an overview of studies using the KD in a
wide panoply of neurologic disorders in which neuroprotection is an essential component.
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INTRODUCTION
The ketogenic diet (KD) is now a proven therapy for drug-resistant
epilepsy (Vining et al., 1998; Neal et al., 2008), and while the
mechanisms underlying its anticonvulsant effects remain incom-
pletely understood (Hartman et al., 2007; Bough and Stafstrom,
2010; Rho and Stafstrom, 2011), there is mounting experimen-
tal evidence for its broad neuroprotective properties and in turn,
emerging data supporting its use in multiple neurological dis-
ease states (Baranano and Hartman, 2008). Even in patients with
medically refractory epilepsy who have remained seizure-free on
the KD for 2 years or more, it is not uncommon for clinicians to
observe that both anticonvulsant medications and the diet can be
successfully discontinued without recrudescence of seizures (Free-
man et al., 2007). This intriguing clinical observation forms the
basis of the hypothesis that the KD may possess anti-epileptogenic
properties.
This review article explores the rationale for using the KD
and related dietary treatments in neurological disorders outside
of epilepsy, and summarizes the clinical experience to date. An
underlying themeof suchdiet-based therapies is that nutrients and
metabolic substrates can exert profound effects on neuronal plas-
ticity, modifying neural circuits and cellular properties to enhance
and normalize function. At a fundamental level, any disease in
which the pathogenesis is inﬂuenced by abnormalities in cellular
energy utilization – and this implies almost every known condi-
tion –would theoretically be amenable to theKD. It is important to
acknowledge that much of the data discussed here are preliminary
and anecdotal, and hence need to be validated by well-controlled
prospective studies. Nevertheless, that diet and nutrition should
inﬂuence brain function should not be altogether surprising, and
there are already abundant clinical and laboratory data linking
defects in energy metabolism to a wide variety of disease states
(Waldbaum and Patel, 2010; Roth et al., 2011; Schiff et al., 2011).
Thus, the potential for interesting and novel applications of the
KD and related dietary therapies is almost limitless (Stafstrom,
2004).
NEUROPROTECTIVE ROLE OF THE KD
Over the past decade, investigators have identiﬁed numerous
mechanisms through which the KD may provide neuroprotective
activity. While a comprehensive discussion of such mechanisms is
beyond the scope of this chapter, a brief discussion is warranted
as such actions are intimately related to disorders that share the
common feature of progressive neurodegeneration and/or cellular
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bioenergetic dysfunction. The reader is referred to recent reviews
for more details on this subject (Gasior et al., 2006; Acharya et al.,
2008; Masino and Geiger, 2008).
Two hallmark features of KD treatment are the rise in ketone
body production by the liver and a reduction in blood glucose
levels. The elevation of ketones is largely a consequence of fatty
acid oxidation. Speciﬁc polyunsaturated fatty acids (PUFAs) such
as arachidonic acid, docosahexaenoic acid, and eicosapentaenoic
acid,might themselves regulate neuronalmembrane excitability by
blocking voltage-gated sodiumand calciumchannels (Voskuyl and
Vreugdenhil, 2001), reducing inﬂammation through activation of
peroxisome proliferator-activated receptors (PPARs; Cullingford,
2008; Jeong et al., 2011), or inducing expression of mitochondrial
uncoupling proteins which reduce reactive oxygen species (ROS)
production (Bough et al., 2006; Kim do and Rho, 2008). Ketone
bodies themselves have been shown to possess neuroprotective
properties, by raising ATP levels and reducing ROS production
through enhanced NADH oxidation and inhibition of mitochon-
drial permeability transition (mPT; Kim do et al., 2007). Along
similar lines of improved bioenergetics, the KD has been shown to
stimulatemitochondrial biogenesis, resulting in stabilized synaptic
function (Bough et al., 2006).
The second major biochemical feature of the KD is the decrease
in glycolytic ﬂux. Reduction of glycolysis is an essential feature
of calorie restriction, which has been shown to suppress seizures
(Greene et al., 2001) as well as prolong the lifespan of numerous
species, includingprimates (Kemnitz,2011;RedmanandRavussin,
2011). While the link between calorie restriction and KD mecha-
nisms remain controversial (Yamada, 2008; Maalouf et al., 2009),
it is clear that both treatments result in reduction of blood glucose,
likely involving reduced glycolytic ﬂux. In that regard, 2-deoxy-d-
glucose (2DG), an analog of glucose that blocks phosphoglucose
isomerase and hence inhibits glycolysis, has been shown to block
epileptogenesis in the rat kindling model by decreasing the expres-
sion of brain-derived neurotrophic factor (BDNF) and its princi-
pal receptor, tyrosine kinase B (TrkB; Garriga-Canut et al., 2006).
Several other important mechanisms contribute to the neuropro-
tective consequences of calorie restriction, including improved
mitochondrial function and decreased oxidative stress (similar to
that seen with ketones and PUFAs), decreased activity of pro-
apoptotic factors, and inhibition of inﬂammatory mediators such
as interleukins and tumor necrosis factor alpha (TNFα; Maalouf
et al., 2009).
In the end, there are likely many other mechanisms that could
contribute to the neuroprotective properties of the KD. Many of
these mechanisms are thought to relate principally to the KD’s
anticonvulsant effects, but some if not all of them could con-
tribute to cellular homeostasis and preventing neuronal injury or
dysfunction. An important caveat, however, is that yet uniden-
tiﬁed mechanisms may operate in diseases outside of epilepsy,
and this possibility presents further opportunities for examin-
ing the pleiotropic effects of this metabolism-based therapy at
a mechanistic level.
THE KD IN EPILEPSY
There is no longer any doubt that the KD is effective in ame-
liorating seizures in patients, especially children, with medically
refractory epilepsy (Vining, 1999; Neal et al., 2008; Freeman et al.,
2009). After its introduction in 1920, the KD was used as a ﬁrst
or second-line treatment for severe childhood epilepsy. With the
introduction of anticonvulsant medications in convenient pill
form, the use of the KD waned, only to resurge later in the early
1990s, due largely to the efforts of concerned parents who brought
the diet back to greater public awareness (Wheless, 2008). Recent
years have witnessed a remarkable surge in research on the KD,
including basic science efforts as well as clinical protocols and tri-
als (Kim do and Rho, 2008; Neal et al., 2008; Kessler et al., 2011).
The KD has now become an integral part of the armamentarium
of most major epilepsy centers throughout the world (Kossoff and
McGrogan, 2005).
THE KD IN AGING
Aging involves the gradual decrease in function, and at times out-
right degeneration, of neurons and neural circuits. It is possible
that by altering energy metabolism with the KD, rates of degener-
ation of certain neural structures and functions might be slowed
(Balietti et al., 2010a). However, KDs may induce differential mor-
phological effects in structures such as the hippocampus, perhaps
as a consequence of region-speciﬁc neuronal vulnerability dur-
ing the late aging process (Balietti et al., 2008). Speciﬁcally, it has
been shown that the medium-chain triglyceride (MCT) form of
the KD may induce detrimental synaptic changes in CA1 stra-
tum moleculare, but beneﬁcial effects in the outer molecular layer
of the dentate gyrus (Balietti et al., 2008). In MCT-fed aged rats
compared to aged rats receiving a normal diet,mitochondrial den-
sity and function in cerebellar Purkinje cells were signiﬁcantly
increased, suggesting that the KD can rescue age-related mito-
chondrial dysfunction (Balietti et al., 2010b). These observations
imply certain risks, but also potential beneﬁts of the KD for the
aging brain. However, the fact that the KD reduces oxidative stress
and its downstream consequences provides a reasonable ratio-
nale for considering this type of treatment to retard the adverse
consequences during aging (Freemantle et al., 2009). As an exam-
ple, T-maze and object recognition performance were improved
in aged rats by KD administration, suggesting a potential func-
tional beneﬁt in cognition (Xu et al., 2010). Finally, it should be
noted that because of its similarities to calorie restriction (as noted
above), the KD is likely to involve other neuroprotective mecha-
nisms that could ameliorate pathological aging – especially when
occurring in the context of neurodegeneration (Contestabile,
2009).
THE KD IN ALZHEIMER DISEASE
There is growing realization that neuronal excitability is enhanced
in patients with Alzheimer disease (AD; Noebels, 2011; Rober-
son et al., 2011). While the essential pathological processes of
AD involves neuronal degeneration with accumulation of abnor-
mal cellular products such as ﬁbrillary plaques and tangles, recent
evidence points to alterations in the function of extant neural cir-
cuits and mitochondrial homeostasis (Kapogiannis and Mattson,
2011). This view is bolstered by the higher incidence of seizures in
patients withAD as compared to the unaffected population (Palop
and Mucke, 2009). Therefore, there is a rationale for hypothe-
sizing that the KD might have a beneﬁcial role in patients with
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AD (Balietti et al., 2010a), in addition to the potential beneﬁts
to the aging process as noted above. One should note, impor-
tantly, that if ketone bodies are indeed the primary mediators that
counter aging and neurodegeneration in AD, implementation of
the KD should be tempered by known age-related differences in
the production and extraction of ketones (i.e., this ismore efﬁcient
in young animals), as well as age-speciﬁc regional differences in
ketone utilization within the brain (Nehlig, 1999).
Clinical studies to date have been equivocal but promising.
A randomized double-blind, placebo-controlled trial of a MCT
KD resulted in signiﬁcantly improved cognitive functioning in
APOε4-negative patientswithADbut not in patientswith aAPOε4
mutation (Henderson et al., 2009). In this study, the primary cog-
nitive end-pointsmeasuredwere themean change frombaseline in
the AD Assessment Scale-Cognitive subscale, and global scores in
theAD Cooperative Study – Clinical Global Impression of Change
(Henderson et al., 2009). This signiﬁcant clinical improvementwas
considered to be secondary to improved mitochondrial function,
since ketone bodies (speciﬁcally, beta-hydroxybutyrate or BHB)
have been shown to protect against the toxic effects of β-amyloid
on neurons in culture (Kashiwaya et al., 2000). Alternatively, the
KD may actually decrease amounts of β-amyloid deposition (Van-
derAuwera et al., 2005). Interestingly, other diets such as the
Mediterranean diet are showing some promise in AD (Gu et al.,
2010), possibly through a reduction in systemic inﬂammation and
improved metabolic proﬁles.
Recent studies have shown a closer linkage of AD to epilepsy.
For example, animal models of AD exhibit neuronal hyperex-
citability and enhanced propensity to seizures (Palop et al., 2007;
Roberson et al., 2011); these models may ultimately allow for
detailed analyses of both cognitive and anticonvulsant effects of
the KD or other dietary manipulations such as calorie restriction.
Transgenic AD mice fed 2DG demonstrated better mitochondrial
function, less oxidative stress, and reduced expression of amyloid
precursor protein and β-amyloid compared to control animals
(Yao et al., 2011).
Another pathophysiological mechanism hypothesized to oper-
ate in AD ties together altered mitochondrial function and glucose
metabolism, i.e., accumulation of advanced glycation endproducts
(AGE; Srikanth et al., 2011).AGE accumulation is a process of nor-
mal aging that is accelerated inAD; proteins are non-enzymatically
glycosylated and this cross-linking of proteins accentuates their
dysfunction. One proposed mechanism is increased ROS and
free radical formation, which, as discussed above, hampers mito-
chondrial function. The intriguing possibility that AGE inhibitors
(e.g., aminoguanidine, tenilsetam, carnosine) could act in concert
with the KD or antioxidants in retarding AD progression remains
speculative at this time.
Thus, there is growing evidence that the KD may be an effec-
tive treatment for AD through a variety of metabolism-induced
mechanisms that reduce oxidative stress and neuroinﬂammation,
and enhance bioenergetic proﬁles – largely through enhanced
mitochondrial functioning. However, caution should be exercised
in extrapolating ﬁndings in animals to humans, as discrepancies
in terms of both clinical efﬁcacy and untoward side-effects have
been noted. For example, adverse reactions to calorie restriction
have been reported in some rodent models (Maalouf et al., 2009),
and in hippocampus, abnormal morphological synaptic changes
have been observed in CA1 stratum moleculare (Balietti et al.,
2008).
THE KD IN PARKINSON DISEASE
The primary pathophysiology in Parkinson disease (PD) is exci-
totoxic degeneration of dopaminergic neurons in the substantia
nigra, leading to abnormalities of movement, and to an increas-
ing extent, in cognition and other cortical functions. How could
the KD beneﬁt patients with PD? Based on the recognition that
ketone bodies may bypass defects in mitochondrial complex I
activity that have been implicated in PD, a small clinical study
demonstrated that 5 of 7 affected patients showed improved scores
on a standard PD rating scale (Vanitallie et al., 2005); however,
given the small sample size, a placebo effect cannot be ruled out.
In animal models of PD produced by 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), BHB administration ameliorated the
mitochondrial respiratory chain damage that ordinarily results
from that toxin (Kashiwaya et al., 2000). Additional evidence sup-
porting the potential beneﬁts of ketone bodies in PD is provided
by in vitro experiments demonstrating the protective effects of
these substrates against mitochondrial respiratory chain dysfunc-
tion induced exogenously by complex I and II inhibitors rotenone
and 3-nitropropionic acid, respectively (Kim do et al., 2010), and
even anti-inﬂammatory actions of the KDonMPTP-induced neu-
rotoxicity (Yang and Cheng, 2010). It would be of interest to
determine whether commercially available treatments that aug-
ment ketonemia – e.g., the MCT-based formulation used in a
recent Alzheimer’s clinical trial (Henderson et al., 2009) – might
beneﬁt patients with PD.
THE KD IN AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive disease
due to degeneration of motor neurons of the cortex and anterior
horn of the spinal cord.As a consequence, voluntarymotor activity
gradually deteriorates, leaving the affected individual profoundly
weak despite largely retained cognitive functioning. The essen-
tial pathophysiological mechanisms that underlie this relentless
disorder are yet to be fully elucidated, but similar to other neu-
rodegenerative disorders, the involvement of energy-producing
systems likely play a role and mitochondrial dysfunction probably
contributes to disease pathogenesis. In this regard, the KD may be
a promising adjunctive treatment for this devastating disease (Siva,
2006), as evidenced in a mouse model of ALS, produced by knock-
ing out the gene encoding the copper/zinc superoxide dismutase
SOD1-G93A, causing progressive muscle weakness and death by
respiratory failure. Administration of a KD to these mutant mice
led to both histological (higher motor neuron counts) and func-
tional improvements (preserved motor function on the rotorod
test) compared to non-KD fed animals (Zhao et al., 2006). How-
ever, the KD did not extend survival time compared to non-KD
fed control mice. Mitochondria from these mutant mice demon-
strated increasedATP synthesis, countering the inhibition of com-
plex I of the electron transport chain. It is important to note that
approximately 20% of the familial cases of ALS have SOD1 muta-
tions, and hence the possibility arises that the KDmay be of beneﬁt
to patients with ALS.
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Onepotentially important consideration in this regard– applic-
able to all neurodegenerative diseases – is determining whether
timing of intervention is crucial for a protective effect by KD
treatment. Neurological disorders in late stages of progressionmay
have such extreme neuronal dysfunction and death to allow a “re-
fueling” with metabolic substrates to help recover integrity and
function. Certainly, this appears to be the case in a small pilot study
of KD treatment in patients with Lafora body disease (Cardinali
et al., 2006).
THE KD IN CANCER
Cells that exhibit the most active metabolic rates (i.e., cancer cells)
are most sensitive to the lack of metabolic energy to fuel their
activity, a well-recognized biochemical phenomenon known as the
Warburg effect. Theoretically, depriving rapidly dividing, highly
metabolic cancer cells of their usual fuel supply, e.g., glucose (by
use of the KD or 2DG), could be clinically therapeutic (Aft et al.,
2002; Pelicano et al., 2006; Otto et al., 2008). Despite this well
documented cellular observation, the KD has only recently been
considered as a clinical treatment in the oncology ﬁeld.
Pioneering work by Seyfried et al. (2011) over the past decade
has shown that animals with experimentally produced brain
tumors placed on a KD exhibit markedly decreased tumor growth
rates, and these remarkable effects appear to be a consequence
of calorie restriction (i.e., reduced blood glucose levels) rather
than KD-induced ketosis (i.e., fatty acid oxidation) as the princi-
pal mechanism. Other investigators have found similar effects of
the KD in animal models. One group found that the KD reduces
ROS production in malignant glioma cells, and gene microar-
ray expression proﬁling demonstrated that the KD induces an
overall reversion to patterns seen in non-tumor specimens and
a reduction in the expression of genes encoding signal trans-
duction pathways and growth factors known to be involved in
glioma growth (Stafford et al., 2010). It is also interesting to note
that PPARα-activated by nutrients such as fatty acids – is now a
target for developing anti-cancer drugs that target mitochondrial
metabolism (Grabacka et al., 2010).
While clinical validation of this phenomenon is not yet forth-
coming, there are several case reports suggesting that the KD
may be efﬁcacious in humans with brain tumors. Nebeling et al.
(1995) reported beneﬁcial effects of an MCT-based diet in two
pediatric patients with advanced stage malignant astrocytomas.
More recently, Zuccoli et al. (2010) described a case study of an
elderly woman with glioblastoma multiforme who was treated
with standard radiotherapy plus concomitant temozolomide ther-
apy together with a calorie-restricted KD, and a complete absence
of brain tumor tissue was noted on FDT–PET and MRI imaging
after 2months of treatment – results the authors attributed in part
to the adjunctive dietary treatment. Further, in a pilot trial of the
KD in 16 patients with advancedmetastatic tumors, six individuals
reported improved emotional functioning and less insomnia, indi-
cating that in some instances, the KDmay lead to improved quality
of life (Schmidt et al., 2011). In contrast, a retrospective exami-
nation of ﬁve patients with tuberous sclerosis complex treated
with the KD indicated either a lack of tumor suppression or fur-
ther tumor growth (Chu-Shore et al., 2010). Thus, it may be that
distinct tumor types within different organ systems may respond
differently to the KD or other dietary treatments and that such
differences may reﬂect variations in the metabolic vulnerability of
speciﬁc tumor types, perhaps through intrinsic differences in the
expression of metabolism-related genes (Stafford et al., 2010).
THE KD IN STROKE
Todate,no clinical trials of theKDhave beenperformed inpatients
with stroke, but several animal studies of hypoxia-ischemia sup-
port the potential beneﬁcial effect of the diet.Most of thesemodels
entail pre-treatment with the KD (or with BHB), resulting in
decreased structural and functional damage from the stroke. For
example, Tai et al. (2008) utilized a cardiac arrest model in rats and
found signiﬁcantly reduced Fluoro-Jade staining in animals that
underwent 25 days of pre-treatment with the KD. These investiga-
tors later determined that these effectswere not due to involvement
of plasmalemmal ATP-sensitive potassium channels (Tai et al.,
2009),whichhave been implicated in ketone body action (Ma et al.,
2007). Other researchers have hypothesized that the neuroprotec-
tive properties of ketone bodies might be related to up-regulation
of hypoxia inducible factor (HIF1-α) which is important in angio-
genesis and anti-apoptotic activity (Puchowicz et al., 2008). In
that study, pre-treatment with BHB (via intraventricular infusion,
followed by middle cerebral artery occlusion) led to signiﬁcant
increases in brain succinate content, as well as elevations inHIF1-α
and Bcl-2, an anti-apoptotic protein. To be clinically meaningful,
of course, a positive effect must be demonstrable after, and not
before, an ischemic event. Nevertheless, such studies imply that
biochemical alterations that favor energy metabolism would be
protective against acute forms of severe brain injury.
THE KD IN MITOCHONDRIAL DISORDERS
As mentioned above, given the growing evidence that the KD
enhances mitochondrial functioning and biogenesis (Bough et al.,
2006; Maalouf et al., 2009; Kim do et al., 2010), it is logical
to ask whether patients with known mitochondrial cytopathies
might derive a beneﬁt from the KD and/or ketone bodies such
as BHB. At the same time, it must be considered that inher-
ent mitochondrial dysfunction might predispose individuals to
adverse toxicities from high fatty acid loads that could overwhelm
β-oxidation within the mitochondrial matrix. Experimental data
described above attest to signiﬁcant improvements in mitochon-
drial function, and many lines of evidence point to the rationale
of therapeutically targeting mitochondrial bioenergetics for other
disease states (Wallace et al., 2010), but is there any clinical evi-
dence in patients with intrinsic mitochondrial disorders? Kang
et al. (2007) reported that the KD was both safe and effective
in 14 pediatric patients with established mitochondrial defects
in complexes I, II, and IV, all of whom had medically intractable
epilepsy. These authors observed that half of these patients became
seizure-free on the KD, and only four patients failed to respond.
Hence, these preliminarydata suggest that theKD is not necessarily
contraindicated in patients with mitochondrial respiratory chain
abnormalities. However, KD treatment is not recommended in
individuals with primary carnitine deﬁciencies [including muta-
tions in carnitine palmitoyl transferase (CPT) I or II and mito-
chondrial translocase] and fatty acid β-oxidation abnormalities
(e.g., medium-chain acyl dehydrogenase deﬁciency; Kossoff et al.,
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2009). Thus, it is critical to determine the speciﬁc mitochondrial
defect when considering treatment with the KD, to avert clinical
deterioration.
THE KD IN BRAIN TRAUMA
Unfortunately, the incidence of brain injury is increasing in both
civilian and military contexts. Brain injury, either due to a pene-
trating injury or to blunt/blast trauma, can lead to severe cogni-
tive and motor consequences. Further, the occurrence of epilepsy
months to years following brain trauma adds to the morbidity of
affected individuals, and speaks to the emergence of hyperexcitable
neuronal circuits over time. Hence, in light of the clinical prob-
lem of post-traumatic epileptogenesis and the fact that the KD
can reduce seizure activity, the notion has emerged that dietary
therapy might ameliorate brain injury and possibly, long-term
consequences such as epilepsy.
Several recent animal studies support this idea, and investi-
gators have principally focused on ketone bodies (Prins, 2008a).
Using a controlled cortical impact (CCI) injury model, Prins et al.
(2005) showed that pre-treatment with a KD signiﬁcantly reduced
cortical contusion volume in an age-related manner that corre-
lated with maturation-dependent differences in cerebral metab-
olism and ketone utilization. Later, they showed that cognitive
and motor functioning was also improved with KD treatment
(Appelberg et al., 2009). Further, using a weight drop model, Hu
et al. (2009) showed that the KD pre-treatment reduced Bcl-2
(also known as Bax) mRNA and protein levels 72 h after trauma,
indicating that apoptotic neurodegeneration could be prevented
with this diet. Consistent with these observations, it was found
that fasting – which shares the key feature of ketosis with the
KD – led to signiﬁcant tissue sparing in brain following CCI
injury, and that again ketosis (with improved mitochondrial func-
tioning) rather than the relative hypoglycemia seen with fasting
was the important determinant of neuroprotection (Davis et al.,
2008).
With respect to anti-epileptogenesis following head injury,
the data regarding KD effects are mixed. KD treatment – either
before or after ﬂuid percussion injury in rats – did not alter later
seizure sensitivity to ﬂuorothyl, even though the degree of hip-
pocampal cell loss was reduced by pre- but not post-treatment
(Schwartzkroin et al., 2010). Similarly, in the lithium–pilocarpine
model of temporal lobe epilepsy, KD treatment prior to induction
led to morphological neuroprotection in the hippocampus but
did not affect latency to onset of spontaneous recurrent seizures
(Linard et al., 2010). In contrast, Jiang et al. (2012) recently
reported that the KD increased after-discharge thresholds and
reduced generalized seizure occurrence in a rat amygdala kindling
model. Thus, at this juncture, there is no consensus regarding
whether the KD is anti-epileptogenic following a variety of trau-
matic insults andmanipulations.However,given the recent ﬁnding
that the KD inhibits the mammalian target of rapamycin (mTOR)
pathway (McDaniel et al., 2011), which has been linked to mod-
ulation of epileptogenesis (McDaniel and Wong, 2011), further
studies in different animal models are clearly warranted. What is
unambiguous, nevertheless, is the age-dependence of the effects
of the KD in ameliorating the consequences of head injury (Prins,
2008b; Deng-Bryant et al., 2011).
THE KD IN PSYCHIATRIC DISORDERS (DEPRESSION)
Mood stabilizing properties of the KD have been hypothesized
(El-Mallakh and Paskitti, 2001), but no clinical studies have been
conducted as of this writing. The potential role of the KD in
depression has been studied in the forced choice model of depres-
sion in rats, which led to a beneﬁcial effect similar to that afforded
by conventional antidepressants (Murphy et al., 2004;Murphy and
Burnham, 2006).
THE KD IN AUTISM
Autism is a neurodevelopmental disorder that affects language
development and social function. The heterogeneous etiologies
leading to autism spectrum disorders, plus the uncertainty about
what causes autism in the majority of “idiopathic” cases, has ham-
pered the development of a universally beneﬁcial treatment, aside
from symptomatic treatment of autism-related behaviors such as
aggression or anxiety. Now, limited clinical evidence raises the
intriguing possibility that the KD might be helpful to alleviate
some of the abnormal behaviors seen in childrenwith autism spec-
trum disorders. Using a KD variant consisting of MCT, 10 of 18
autistic children demonstrated moderate or signiﬁcant behavioral
improvement (by a blinded rater) after a 6-month trial of pro-
viding the diet for 4weeks of KD diet treatment alternating with
2weeks of normal diet, in 6-week cycles (Evangeliou et al., 2003).
This study was carried out on the island of Crete, where the fre-
quency of autism is high but the possibility of genetic inbreeding
is also signiﬁcant. Therefore, these ﬁndings need to be interpreted
cautiously and larger longitudinal studies are needed. The poten-
tial involvement of adenosine, an endogenous neuromodulator
and anticonvulsant, in ameliorating autistic behaviors raises the
possibility of overlap with KD mechanisms (Masino et al., 2011).
As a caveat, many children with autism poorly tolerate changes in
dietary and other routines, which could impact implementation
of dietary therapies, which require strict adherence.
THE KD IN MIGRAINE
Migraine is a paroxysmal neurological disorder having con-
siderable clinical phenotypic overlap with epilepsy (Rogawski,
2008).Although the intrinsicmechanisms underlying seizures and
migraine attacks differ in many fundamental respects, there are
theoretical reasons to consider the KD for chronic migraine. Both
disorders involve paroxysmal excitability changes in the brain, and
there is considerable overlap in the arrayof pharmacological agents
used to treat these conditions.Although itmight seemunlikely that
an individual with migraine would undertake such a complicated
dietary regimen as the KD, in light of suboptimal alternatives, this
choice is worthy of consideration, particularly in the medically
refractory population (Maggioni et al., 2011).
Interestingly, the ﬁrst report of using the KD for migraine came
in 1928, only a few years after the diet’s ﬁrst use for epilepsy
(Schnabel, 1928). Nine of 28 patients reported “some improve-
ment,” although the validity of this clinical study is uncertain and
some patients admitted poor compliance. Compliance might be
better with the less restrictive modiﬁed Atkins diet, which has
also shown promise for migraine treatment (Kossoff et al., 2010).
Other case reports exist but there are no large clinical series or
trials. Notwithstanding this limitation, laboratory investigations
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have found that both short-term and long-term treatment with
either MCT or long-chain triglyceride forms of the KD resulted
in a signiﬁcant reduction in the velocity of cortical spreading
depression (CSD) velocity in immature rats (de Almeida Rabello
Oliveira et al., 2008). Another intriguing aspect of this study was
the observation that triheptanoin – an anaplerotic substrate that
enhances tricarboxylic acid cycle function – had a notable effect
in retarding CSD, consistent with a later report that triheptanoin
supplementation raised pentylenetetrazol tonic seizure threshold
and delayed the development of corneal kindled seizures (Willis
et al., 2010).
SUMMARY
Despite the relative lack of clinical data, there is an emerging lit-
erature supporting the broad use of the KD (and its variants)
against a variety of neurological conditions. These preliminary
studies are largely based on the fundamental idea that metabolic
shifts may lead to neuroprotective actions (Gasior et al., 2006;
Maalouf et al., 2009). How can a simple dietary change lead to
improvement in disorders with such a huge span of pathophys-
iological mechanisms? Alterations in energy metabolism appear
to be a common theme. So while the mechanisms through which
the KD exerts such effects are likely diverse (Maalouf et al., 2009;
Rho and Stafstrom, 2011), there may indeed be one or more com-
monﬁnal pathways that aremechanistically shared.Ultimately, the
details of how that altered metabolism reduces neuronal excitabil-
ity, abrogates ongoing neurodegeneration, or mitigates functional
disability remain unknown. Herein lay rich opportunities for fur-
ther investigation, in both the laboratory and the clinic, in the
broad realm of translational neurosciences.
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